Sun Pharma Sees LIC Cross 5% Holding Threshold
New Delhi: The Life Insurance Corporation of India (LIC) has increased its stake in Sun Pharmaceutical Industries Limited to over 5 percent following a market purchase of equity shares.
The disclosure was made under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
According to the disclosure dated January 14, 2026, LIC informed Sun Pharmaceutical Industries Limited that it has crossed the 5 percent shareholding threshold after acquiring additional equity shares through market transactions. The disclosure was submitted to the Company Secretary of Sun Pharma in compliance with SEBI norms.
In its communication issued from LIC’s Central Office, Investment Department, Yogakshema, Jeevan Bima Marg, Mumbai, LIC stated that the disclosure pertains to a person holding more than five percent shares in a listed company. The filing was signed by the Assistant Secretary (Investment – Back Office) and included details such as DP IDs, Client IDs, and PAN, as required under regulatory provisions.
As per Annexure 2 of the disclosure, the target company is Sun Pharmaceutical Industries Limited, whose equity shares are listed on both the National Stock Exchange of India (NSE) and BSE Limited. LIC clarified that it does not belong to the promoter or promoter group of the Company.
Prior to the acquisition, LIC held 11,98,76,648 equity shares of Sun Pharmaceutical Industries Limited, representing 4.996 percent of the Company’s total shareholding. LIC subsequently acquired an additional 2,02,500 equity shares, accounting for 0.008 percent of the paid-up share capital, through market purchase on January 13, 2026.
Following the transaction, LIC’s total shareholding in Sun Pharmaceutical Industries Limited increased to 12,00,79,148 equity shares, equivalent to 5.004 percent of the Company’s total equity share capital.
The disclosure further noted that Sun Pharmaceutical Industries Limited’s equity share capital and total voting capital remained unchanged at ₹2,39,93,34,970 before and after the acquisition. Details relating to diluted share capital were stated to be not applicable.
The disclosure was executed at Mumbai on January 14, 2026, with copies marked to BSE Limited and NSE Limited, in accordance with statutory disclosure requirements.
